Caris Life Sciences, Inc. CAI
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 4.42% | 21.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.42% | 21.99% | |||
| Cost of Revenue | 10.65% | 12.42% | |||
| Gross Profit | 1.50% | 27.06% | |||
| SG&A Expenses | 7.33% | 14.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.13% | 12.28% | |||
| Operating Income | -28.26% | 409.77% | |||
| Income Before Tax | 2,848.21% | 4.66% | |||
| Income Tax Expenses | 6,960.87% | 117.16% | |||
| Earnings from Continuing Operations | 2,494.03% | -24.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2,494.03% | -24.90% | |||
| EBIT | -28.26% | 409.77% | |||
| EBITDA | -22.54% | 223.42% | |||
| EPS Basic | 2,434.78% | -27.78% | |||
| Normalized Basic EPS | -31.80% | 3,985.71% | |||
| EPS Diluted | 2,273.91% | -27.78% | |||
| Normalized Diluted EPS | -34.38% | 3,985.71% | |||
| Average Basic Shares Outstanding | 0.36% | 0.12% | |||
| Average Diluted Shares Outstanding | 4.33% | 0.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||